A comparison of covariate selection techniques applied to pre-exposure prophylaxis (PrEP) drug concentration data in men and transgender women at risk for HIV

J Pharmacokinet Pharmacodyn. 2021 Oct;48(5):655-669. doi: 10.1007/s10928-021-09763-y. Epub 2021 May 19.

Abstract

Pre-exposure prophylaxis (PrEP) containing antiretrovirals tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) can reduce the risk of acquiring HIV. Concentrations of intracellular tenofovir-diphosphate (TFV-DP) measured in dried blood spots (DBS) have been used to quantify PrEP adherence; although even under directly observed dosing, unexplained between-subject variation remains. Here, we wish to identify patient-specific factors associated with TFV-DP levels. Data from the iPrEX Open Label Extension (OLE) study were used to compare multiple covariate selection methods for determining demographic and clinical covariates most important for drug concentration estimation. To allow for the possibility of non-linear relationships between drug concentration and explanatory variables, the component selection and smoothing operator (COSSO) was implemented. We compared COSSO to LASSO, a commonly used machine learning approach, and traditional forward and backward selection. Training (N = 387) and test (N = 166) datasets were utilized to compare prediction accuracy across methods. LASSO and COSSO had the best predictive ability for the test data. Both predicted increased drug concentration with increases in age and self-reported adherence, the latter with a steeper trajectory among Asians. TFV-DP reductions were associated with increasing eGFR, hemoglobin and transgender status. COSSO also predicted lower TFV-DP with increasing weight and South American countries. COSSO identified non-linear relationships between log(TFV-DP) and adherence, weight and eGFR, with differing trajectories for some races. COSSO identified non-linear log(TFV-DP) trajectories with a subset of covariates, which may better explain variation and enhance prediction. Future research is needed to examine differences identified in trajectories by race and country.

MeSH terms

  • Adenine / analogs & derivatives
  • Adenine / metabolism
  • Adenine / therapeutic use
  • Adult
  • Anti-HIV Agents / metabolism*
  • Anti-HIV Agents / therapeutic use*
  • Female
  • HIV Infections / prevention & control*
  • Humans
  • Male
  • Medication Adherence
  • Organophosphates / metabolism
  • Organophosphates / therapeutic use
  • Pre-Exposure Prophylaxis / methods
  • Tenofovir / metabolism
  • Tenofovir / therapeutic use
  • Transgender Persons

Substances

  • Anti-HIV Agents
  • Organophosphates
  • tenofovir diphosphate
  • Tenofovir
  • Adenine